Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from national surgical adjuvant breast and bowel project B-23

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 931-942

  Fisher, B ^a   Anderson, S ^a   Tan Chiu, E ^a   Wolmark, N ^a   Wickerham, D L ^a   Fisher, E R ^a   Dimitrov, N V ^a   Atkins, J N ^a   Abramson, N ^a   Merajver, S ^a   Romond, E H ^a   Kardinal, C G ^a   Shibata, H R ^a   Margolese, R G ^a   Farrar, W B ^a  

^a NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PLACEBO; TAMOXIFEN;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; GRANULOCYTOPENIA; HEART INFARCTION; HORMONAL THERAPY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT OUTCOME;

EID: 0035865147     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.931     Document Type: Article

References (41)

1. Consensus conference: Adjuvant chemotherapy for breast cancer
2. Milan adjuvant trials for stage I-II breast cancer
3. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors
4. A randomized clinical trial evaluating tamoxifen in the treatment of patients with nodenegative breast cancer who have estrogen-receptor-positive tumors
5. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: An intergroup study
6. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer
7. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer
8. Improved survival amongst patients treated with adjuvant tamoxifen after mastectomy for early breast cancer
9. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer: Analysis at six years by 'Nolvadex' Adjuvant Trial Organisation
10. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: Analysis at eight years by Nolvadex Adjuvant Trial Organization
11. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial - Report from the Breast Cancer Trials Committee
12. Treatment of primary breast cancer with chemotherapy and tamoxifen
13. Adjuvant endocrine therapy in the management of primary breast cancer
14. Tamoxifen induces accumulation of MCF-7 human mammary carcinoma cells in the GO/GI phase of the cell cycle
15. Inhibition of protein kinase C by tamoxifen
16. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase
17. Effect of tamoxifen on serum insulin-like growth factor-1 levels of stage 1 breast cancer patients
18. Modulation of natural killer cell activity by tamoxifen in stage 1 postmenopausal breast cancer
19. Long-term adjuvant tamoxifen therapy for breast cancer
20. Induction of transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells
21. Inhibition of angiogenesis by antiestrogens
22. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from NSABP B-16
23. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive rumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
24. Maximum utilization of the life table in analyzing survival
25. Evaluating differences in survival between two groups of patients
26. Regression models and life tables
27. Statistical aspects of the analysis of data from the retrospective study of disease
28. Asymptotically efficient rank invariant test procedures
29. Testing for qualitative interactions between treatment effects and patient subsets
30. Tamoxifen for early breast cancer: An overview of the randomized trials
31. CMF versus CAF ± tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: Update of tamoxifen results
32. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer
33. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the NSABP trial
34. Antagonism of the cytocidal activity and update of melphalan by tamoxifen by human breast cancer cells in vitro
35. Antiestrogens antagonize melphalan but not cyclophosphamide cytotoxicity in human breast cancer cells by estrogen receptor independent mechanisms
36. Endocrine pharmacology of antiestrogens as antitumor agents
37. The pharmacology and clinical uses of tamoxifen
38. Effects of tamoxifen and 4′-hydroxytamoxifen on the PNR-1 and PNR-2 estrogen-regulated RNA's in human breast cancer cells
39. Anti-steroidal and anti-growth factor activities of anti-estrogens
40. Steroid hormones and growth factors in breast cancer
41. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma